Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I can't see a rational forecast for good at the moment, board of directors are an interesting question, if they exercised no rights, how can they look at their peers without guilt
True on Fridays, disagree shorting or HB either is root cause. Company absolutely needed Europe to perform over last 6 years. Who knows if Europe given another 10 years, but time is money at the tune of $25 million per year, no way
It is a clear case of desperation which translates to likely a rights offering producing way too few dollars. It is truly amazing, delcath never had such horrific financing from 2003 thru 2015. Humpty dumpty is broke, what a feat if this nightmare ends well
Desperate action means when rights were first announced it was left to the imagination the ugliness, too late once funds are committed by those that got in
A case of all the king's horses etc.., such as board of directors, that insider buying is sure a head scratcher, just as today's trading. To modify Forrest Gump, smart management is smart does, so I wait
Stocks are not institutions of trust, just sometimes a happy accident etc..
Correct, fraud claims don't work for me. But jeez louise, it might as well be fraud the bad deals to struggle for life, I will gamble sometimes on uncertainty, but right now definitely not.
Why even for support purposes paying over $2 for common? Goofing up in my opinion as the aug 31 deal just announced seems to say rights offering is a stinker, this may yet be a good buy but at what price and when?
A strong possibility, but it is still a good chunk of change, so possibilities for hope
The only thing known is less than $50 million as supposed gross cap. I am bullish about the enormous volume today, somebody is not walking away so ...
Current market cap is tiny and useless imo until and if many millions of dollars are raised, so the current offering attempt ends sep 26. Then maybe a clearer picture. Bullish sentiment is absent on this board, I am hoping we all want to know what the fat lady says about sep 26
That is exactly why this company can't find a partner or buyer, wrong technology. Europe has shown the way with paltry revenue. I remember when Hobbs (the pumper chief) said Europe had more potential than U.S. market.
Still believe if the company hit successful end of phase 3, market cap of $100 m or less would be a bargain for a TRADE
I would say zero chance of accident if this company makes it to approval, now if we were talking miracles combined with doing some things right, I would say that is how it looks right now given $50 million is a scary but realistically needed goal
The real topic is success if if and when, sticking with 394 shares, reading tea leaves daily
I am not a one activity horse. All it takes to disprove the excessively harsh claims imo is somehow making it to FDA approval, that is the gold standard of deity here. If folks don't believe that is Simspon's desire, I submit look again at who is in denial. Now risk/reward is a different story
I prefer to err on the side of a positive view - but not risking my neck without seeing a better picture develop. Every view here should be subject to revised estimates of character depending on events
I am not currently bullish over this situation, but apparently trading indicates bulls of some stripe
How about if she is not a crook, skates on thin ice as little as possible, straight shooter except when trapped by the serious conditions of near drowning due to a far more difficult job than is acknowledged.
Nobody has ever proven Simpson is uninterested in deals with big pharm, that is why I refer to her as the Goddess, fair is fair
If you strike that part, she was saying big pharm is not interested, my theme is OM is too small combined with it is a pain to go through 4 to 6 treatments or more hoping, some are willing, some are not
A company with a failed product before FDA and high expenses, a bad speculation. Kudos historically to smart money, sour grapes has a utilitarian purpose until IF/maybe some corner is reached, in the meantime happy to be on sidelines watching, my 394 shares is plenty enough exposure
Trust, I have more than most since there is such a tiny supply. My current thinking is the company needs to have raised $35 million so far in case of an extension press release for me to try for rights
Other words this company is only worth a look if big money piles in especially if including big insider money. If one assumes by early next year 40 million shares outstanding, $2 would be a bargain. To assume more shares on the way late 2019, 50 million shares at $2 still looks like a bargain. Bidding up from $2, more dicey
Too much love for simplistic analysis. If they do raise a lot of money, I will probably join, money talks
It has been a very clinically timeline disappointing company as 5 years since FDA rejection and maybe ate up around $120 million. Amazing when market cap average over last 2 years about $5 million, if one Strikes June 2017 runup and the post euphoric level
It is obvious the vast majority of people who touched delcath have little interest here, but when and where and what regarding the fat lady?
Good point. Now if they were to raise $30 million so far and announced thus, then people might want to jump in, otherwise
Highly likely and would have to guess potential range raised so far of less than $5 million to maybe over $30 million in extension case
Okay 3 quarters back was 450, so if 150 in last 3 quarters, 200 per year approx. so could be $15,000 or less per filter reimbursement
No once again, 150 treatments per year a rough estimate at $20K would be $3 million revenue. Maybe on upper end approaching 250 treatments per year but I doubt it
It is not about how much delcath gets. There are only 600 treatments plus commercially, maybe now 150 treatments per year.
Why is German reimbursement not doing more for revenue? I don't know if reimbursement is done if other than OM. Given failure of previous p3 and ticklish FDA, I give Simpson all the rope she wants clinically. If I had to guess before this offering is done, 50 percent chance finish line will be reached, as my faith is low on the business side for my goddess
Well first it is interesting that FDA is not as much a terrorist group as in 2010 era. Also who knows whether each time for designs whether FDA pushed the choice or the company.
First time around delcath had a poor quality filter plus did not provide additional meds to counter side effects, so trying to get 6 treatments was probably near impossible, 3 max treatments in study.
In original study clearly OS was still better compared to those in the control group that did not cross. The Crossover folks though lived longer than CS only group, likely because they did not have an early pounding from CS, so were like fresh troops
It is on a relative basis. The most disenchanted investors since the days of Hobbs were created after the ignoring of most important filing in company history so far. Part 2 to this story Simpson imo is smart clinically, trying hard to reach the finish line. If this offering fails, she will probably fail. One component she can't control much, the OM demand seems too lackluster to me
Agreed, it saved those who treated the filing accurately from some of the following months of maybe harshest stock drop in history of company
Well the crooked part to this company is when it is floundering badly as Tickerpicker illustrated, the company will grab at anything and the worse it is, the less clear the company will be. Exception was the forthright filing last July of 2017 which investors conveniently never refer to
I don't recall saying much about forecasting how convertible would go for part 1, but part 2 after 350 to 1 and price plunge I even thought for a while probable bankruptcy. Bankruptcy topic is back strong again because this offering is too unknown, I am staying away from offering as the 1 cent exercise of warrants is not a faith builder
The previous p3 had crossover and was a contributing factor to failing before FDA. I am of the opinion that real world demand may be too low despite a decent technology, ICC has to contribute to revenue and that is likely too many years away
It may never be proved that she is totally without honor, plenty of reason to suspect there was no outside interest in the company, time for people to look in the mirror, way past time, If bod member puts up $3 million, it will then be super way past time, give me $50 million or give me death
Just the facts, there is no proof that Simpson would have been against taking offers in 2016 before the convertible deal. If she was against, she is a thug in women's clothing.